CytomX Therapeutics, Inc. Operating Lease Liability
CytomX Therapeutics, Inc. (CTMX) had Operating Lease Liability of $9.38 million as of 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2025-03-06
- 2024-12-31: Operating Lease, Liability $9.38M.
- 2023-12-31: Operating Lease, Liability $13.97M.
- 2022-12-31: Operating Lease, Liability $18.06M.
- 2021-12-31: Operating Lease, Liability $21.67M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2024-12-31 | $9.38M 10-K · filed 2025-03-06 | |
| 2023-12-31 | $13.97M 10-K · filed 2024-03-11 | |
| 2022-12-31 | $18.06M 10-K · filed 2023-03-27 | |
| 2021-12-31 | $21.67M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | $22.53M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $23.32M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $24.10M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $24.87M 10-K/A · filed 2023-03-27 | |
| 2020-09-30 | $25.62M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $26.32M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $27.01M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $27.68M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $28.34M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $28.95M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $27.68M 10-Q · filed 2020-05-07 | $29.55M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |